EU Approves Blenrep Combinations for Relapsed/Refractory Multiple Myeloma
GSK plc has announced that the European Union has approved its drug Blenrep (belantamab mafodotin) in combination therapies for the treatment of adults with relapsed or refractory…
Read More...
Read More...
